Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Zentalis (ZNTL) to $4 from $8 and keeps an Equal Weight rating on the shares after the company reported Q3 earnings and highlighted progress with enrollment ongoing in the DENALI Part 2a study for azenosertib in platinum resistant ovarian cancer. The firm has fine tuned its azenosertib revenue estimates, having increased its PROC revenue estimate, removed revenues from non-gynecological indications and decreased its peak sales estimate to $511M from $867M previously.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC
- Zentalis Pharmaceuticals Reports Q3 2025 Financial Results
- Zentalis reports Q3 EPS (37c), consensus (48c)
- Strategic Advancements and Promising Developments Drive Buy Rating for Zentalis Pharmaceuticals
- Zentalis board member Letai frontrunner to lead NCI, STAT reports